Recurrence Free Survival After Curative Resection of Non-small Cell Lung Cancer Between Inhalational Gas Anesthesia and Propofol-based Total IntraVenous Anesthesia: a Multicenter, Randomized, Clinical Trial

What this Trial Is About

Researchers are studying patients with non-small cell lung cancer (NSCLC) to compare the effects of two types of anesthesia on cancer recurrence after surgery. The trial aims to test whether patients who receive total intravenous anesthesia (TIVA) with propofol have a higher recurrence-free survival compared to those who receive volatile inhaled anesthetics. This is a multicenter, randomized, double-blind phase 4 trial involving 22 international sites and adult patients undergoing lung resection surgery with curative intent for NSCLC. Participants will be randomly assigned to one of two groups: the TIVA group, which receives propofol for induction and maintenance of general anesthesia, or the GAS group, which receives one or more volatile anesthetics such as sevoflurane, desflurane, or isoflurane for anesthesia. In the GAS group, additional co-induction agents like propofol or midazolam may be used at the anesthesiologist's discretion. The trial does not standardize other aspects of patient care but balances potential confounders between groups. During the study, participants will be followed for outcomes including recurrence-free survival within 3 years after surgery, overall survival, and complications occurring within 7 days post-surgery or earlier at discharge. Data will be collected through a secure web-based system, and enrollment of 5,384 patients is planned to provide sufficient power for detecting differences in outcomes. The trial is expected to end by the end of 2028, with safety and effectiveness monitored throughout the study period.

Anesthesia and Non-small Cell Lung Cancer Recurrence